BridgeBio Oncology Therapeutics, Inc. (BBOT) is currently trading at $7.4 with a Wall Street consensus price target of $25.11, implying potential upside of 239.3% over the next 12 months. 9 analysts currently cover BBOT, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $41.0, while the most cautious has a target of $18.0.
BBOT operates in the Healthcare sector with a market capitalisation of $593M. The stock is down 39.8% year-to-date and is currently trading near the lower end of its 52-week range of $7.0 – $14.87.
Other Healthcare stocks with comparable size and valuation.
Upgrade/downgrade history for BBOT, with each firm's 90-day track record across all stocks we track. See full firm rankings →
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →